Except for endoglin, which is used to highlight activated tumor BVs in renal cell carcinomas (in conjunction or not with other common endothelial markers) [18,19,20], there is sporadic data on B7-H3 [21] or endocan [22] expression in newly formed blood vessels from renal cell carcinomas, but there is no validated data on their use as therapeutic targets. This evidence concerns the gene CD276 and renal cell carcinoma.